Clinical Trial Update: Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 protocol design update for evaluating immunity from bivalve fluids in coronavirus infections including SARS and COVID-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Infections
• Sars

Drugs mentioned

• Bivalve Fluids From Anodonta cygnea

Snippet

Sponsor: Universidade do Porto | Conditions: Coronavirus Infections, Coronavirus Sars-Associated | Phase 2 | Status: UNKNOWN